Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | AR | P10275 | 8/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7644170 | 0.84 | TSHR (0.53) | MAPTMAPK1NPSR1GAASMN1; SMN2 | |
| SCHEMBL7639368 | 0.83 | TSHR (0.59) | MAPTMAPK1NPSR1TDP1GAA | |
| SCHEMBL7642334 | 0.81 | GAA (0.54) | MAPTMAPK1NPSR1TDP1GAA | |
| SCHEMBL7635078 | 0.79 | CASP1 (0.55) | MAPTMAPK1NPSR1L3MBTL1TSHR | |
| SCHEMBL7640668 | 0.79 | MAPT (0.57) | MAPTARGAARAB9APRKCZ | |
| SCHEMBL17707781 | 0.79 | TSHR (0.53) | MAPTMAPK1NPSR1GAARAB9A | |
| SCHEMBL2650272 | 0.78 | MAPT (0.57) | MAPTARGAARAB9APRKCZ | |
| SCHEMBL9979815 | 0.76 | AR (0.64) | MAPTARGAARAB9APRKCZ | |
| SCHEMBL8490992 | 0.76 | TDP1 (0.70) | MAPTMAPK1NPSR1TDP1GAA | |
| SCHEMBL4420346 | 0.76 | SMN1; SMN2 (0.64) | MAPTMAPK1NPSR1TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6340772-B2 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE | NIPPON KAYAKU CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | TOYA TETSUYA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-6271418-B1 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE DERIVATIVES. | NIPPON KAYAKU CO., LTD. (JP) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | AHR, CYP3A4, CYP4B1 | MAPT 4234/4885AR 686/4885MAPK1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.